Airway microbiota in patients with synchronous multiple primary lung cancer: the bacterial topography of the respiratory tract

we analyzed the characteristics of the respiratory microbiome, which was collected from different sites and using different sampling methods. Overall design: We used the Antakli modifications as the basic criteria for the definition of sMPLC. The details are as follows: (1) one lesion in each patient must be diagnosed as an adenocarcinoma; (2) that the lesions are in anatomically distinct regions; (3) that there are no systemic metastases; (4) that there is no mediastinal spread as confirmed by postoperative pathology; and (5) possessing two or more of the following: (i) one tumor diagnosed as an adenomatous tumor, i.e., minimally invasive carcinoma, or invasive AD[3], and another tumor diagnosed as either squamous carcinoma or small cell lung cancer; (ii) different driver gene mutations; and (iii) different biomarker patterns[11]. The inclusion criteria were as follows: (1) patients diagnosed with sMPLC, as previously described, and all lesions located in the right upper lobe (RUL); (2) aged =18 years; (3) no contraindications for pulmonary surgery, i.e., distant metastasis, bleeding tendency, blood clotting disorders, cardiopulmonary insufficiency, severe arrhythmia or hypertension, pulmonary hypertension, and acute respiratory infection; (4) no other prior therapies; (5) expected survival >2 months; (6) without a history of other primary malignant tumors; (7) agreeing to participate in this study. Exclusion criteria included patients with poorly controlled diabetes, prior cerebrovascular events, active second malignancy, uncontrolled concommitant illness, or other conditions that might affect their participation in the study. We used the Antakli modifications as the basic criteria for the definition of sMPLC [10]. The details are as follows: (1) one lesion in each patient must be diagnosed as an adenocarcinoma; (2) that the lesions are in anatomically distinct regions; (3) that there are no systemic metastases; (4) that there is no mediastinal spread as confirmed by postoperative pathology; and (5) possessing two or more of the following: (i) one tumor diagnosed as an adenomatous tumor, i.e., minimally invasive carcinoma, or invasive AD[3], and another tumor diagnosed as either squamous carcinoma or small cell lung cancer; (ii) different driver gene mutations; and (iii) different biomarker patterns[11]. The inclusion criteria were as follows: (1) patients diagnosed with sMPLC, as previously described, and all lesions located in the right upper lobe (RUL); (2) aged =18 years; (3) no contraindications for pulmonary surgery, i.e., distant metastasis, bleeding tendency, blood clotting disorders, cardiopulmonary insufficiency, severe arrhythmia or hypertension, pulmonary hypertension, and acute respiratory infection; (4) no other prior therapies; (5) expected survival >2 months; (6) without a history of other primary malignant tumors; (7) agreeing to participate in this study. Exclusion criteria included patients with poorly controlled diabetes, prior cerebrovascular events, active second malignancy, uncontrolled concommitant illness, or other conditions that might affect their participation in the study.